💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Max Healthcare Institute Limited is an India-based integrated healthcare provider. The Company operates through a single segment, namely Medical and Healthcare Services. It provides a wide array of services, including advanced cardiac care, lung transplants, prostate laser…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, slow-growing business, reasonably priced.
Max Healthcare is scored on the pharma / healthcare framework. It keeps a healthy 16.9% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.13× reported profit. Free cash flow is worth about -0.1% of its market value.
Over the last 3 years revenue compounded at 22%/yr and profit at 9%/yr. Book value has grown 13%/yr. Return on equity is a healthy 12.2%. In the latest quarter profit grew 28% versus the prior quarter.
At 63× earnings, the stock sits at the 24th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price already implies ~25%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 65.87 | 75.62 | better |
| P/B | 8.02 | 3.49 | worse |
| EV/EBITDA | 36.39 | 19.95 | worse |
| ROE | 12.18 | — | — |
| ROCE | 13.24 | 10.81 | better |
| ROA | 7.37 | 3.84 | better |
| Quick Ratio | 0.84 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
| Aster DM Healthcare | 171.4 | 14.8 | 8.5% |
Revenue has grown every year across all 4 financial years shown. 22% CAGR over 3 years — high-growth territory. Growth is decelerating — latest year grew slower than the year before.
Revenue is outpacing profit (22% vs 9%) — costs are rising faster than the top line. The latest year saw a +34% swing — check if it's a one-off or structural.
Operating margin has compressed from 23% to 20% — costs or competition are eating into profitability. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 13% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
9% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Investing outflows exceed operating cash — the company relies on external funding to finance expansion. Raising capital despite positive cash flow — could signal expansion plans or opportunistic fundraising.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building. Run-rate stepping up — recent quarters average 17% above earlier ones.
Profit jumped 28% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold just 23.7% — widely held; sentiment-driven. FIIs trimmed 10.0pp — foreign money is rotating out. MF holding up 5.2pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.